UNC Immunotherapy Training Grant (IM-TAG)

北卡罗来纳大学免疫治疗培训补助金 (IM-TAG)

基本信息

  • 批准号:
    10767617
  • 负责人:
  • 金额:
    $ 16.51万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-09-15 至 2028-08-31
  • 项目状态:
    未结题

项目摘要

Abstract: This is a training program from the University of North Carolina at Chapel Hill (UNC-CH) to train postdoctoral fellows in basic, translational or clinical research focusing on tumor immunotherapy, tumor immunology or stem cell transplantation immunology. The UNC Immunotherapy Training Grant (IM-TAG) is led by an exceptional mentor, Jonathan Serody MD, who is assisted by two superb Associate Directors in Barbara Savoldo MD PhD and Benjamin Vincent MD. This training proposal is supported by a nationally renowned mentorship group and exceptional facilities for translation of tumor and transplantation immunology to the clinic. Additionally, there are world-class investigators that make up the Internal Advisory Committee and External Advisory Board. The focus of IM-TAG is significantly underrepresented in training programs leading to a paucity of investigators working in these areas. IM-TAG supports the training of two postdoctoral fellows yearly. There are 11 Professors, and eight Associate Professors, with outstanding qualifications who serve as mentors. We have identified two exceptional Assistant Professors, who serve as co-mentors. These investigators’ interests include 1) vaccine design and vector generation, 2) adoptive cellular therapy, 3) the role of immune cells in the tumor microenvironment (TME), 4) immunogenomic assessment of TME, 5) enhancing our understanding of the biology of the graft-versus-tumor response and 6) approaches to manage acute and chronic graft-versus-host disease. There are innovative mechanisms for training that include 1) didactic coursework in statistical design, 2) immunogenomic coursework and data evaluation overseen by world experts in tumor immunogenomics, and 3) participation in Immunotherapy Working Groups, which are translational teams that assist in the development of novel immunotherapies, allowing trainees to be involved in the development of INDs and clinical trials. We have a comprehensive approach to training underrepresented minorities, including a summer course for undergraduate students to provide them with hands-on experience in immunotherapy or transplantation immunology. Strengths of the program include 1) an extremely well-funded group of mentors with substantial experience training postdoctoral fellows, 2) an outstanding leadership group with a long history of leading collaborative research proposals, 3) and the presence of a world-class vaccine and transplantation infrastructure that trainees can access. This program combines the mentors, foundation, and resources of a nationally recognized tumor immunology, cancer immunotherapy and transplantation immunology program with novel approaches to enhance the vertical training of underrepresented individuals and enhance the bench to bedside development of therapeutics by individuals who are trained in this program.
摘要: 这是北卡罗来纳州查佩尔山大学(UNC-CH)的一个博士后培训项目 从事肿瘤免疫治疗、肿瘤免疫学或干细胞研究的基础、转化或临床研究的研究员 细胞移植免疫学免疫治疗培训补助金(IM-TAG)由一位杰出的 导师,乔纳森Serody医学博士,谁是由芭芭拉Savoldo医学博士博士两个一流的副主任协助 和医学博士本杰明·文森特这项培训计划得到了一个全国知名的辅导小组的支持, 将肿瘤和移植免疫学转化为临床的特殊设施。另外存在 世界一流的调查人员组成了内部咨询委员会和外部咨询委员会。重点 的IM-TAG在培训项目中的代表性明显不足,导致缺乏在 这些地区 IM-TAG每年支持两名博士后研究员的培训。有11名教授和8名副教授 具有优秀资格的教授担任导师。我们已经确定了两个特殊的助理 教授,担任共同导师。这些研究者的兴趣包括1)疫苗设计和载体 代,2)过继细胞治疗,3)免疫细胞在肿瘤微环境(TME)中的作用,4) TME的免疫基因组学评估,5)增强我们对移植物抗肿瘤生物学的理解 反应和6)管理急性和慢性移植物抗宿主病的方法。有创新 培训机制,包括1)统计设计的教学课程,2)免疫基因组学课程 由世界肿瘤免疫基因组学专家监督和数据评估,以及3)参与免疫治疗 工作组是协助开发新型免疫疗法的翻译团队, 允许学员参与IND和临床试验的开发。我们有一个全面的 培训代表性不足的少数群体的方法,包括为本科生开设暑期课程, 为他们提供免疫治疗或移植免疫学方面的实践经验。 该计划的优势包括:1)一个资金雄厚、经验丰富的导师团队 培养博士后研究员,2)具有悠久的领导合作历史的优秀领导团队 研究建议,3)以及世界一流的疫苗和移植基础设施的存在, 可以访问。这个计划结合了导师,基金会,和资源的一个国家公认的肿瘤 免疫学、癌症免疫治疗和移植免疫学项目, 加强对代表性不足的个人的垂直培训,并加强从替补到床边的发展, 接受过该项目培训的个人提供的治疗方法。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Jonathan S. Serody其他文献

Differential Impact of Dose Escalated Busulfan on Allogeneic Transplant for High, Intermediate and Low Risk Disease
  • DOI:
    10.1016/j.bbmt.2014.11.494
  • 发表时间:
    2015-02-01
  • 期刊:
  • 影响因子:
  • 作者:
    Thomas C. Shea;Christine M. Walko;Yunro Chung;Anastasia Ivanova;Kamakshi V. Rao;James Coghill;Stefanie Sarantopoulos;William A. Wood;Paul Armistead;Don A. Gabriel;Jonathan S. Serody
  • 通讯作者:
    Jonathan S. Serody
The Composition of Acute Myeloid Leukemia Cell Differentiation States Predicts Response to Immune Checkpoint Blockade
急性髓系白血病细胞分化状态的组成预测免疫检查点阻断的反应
  • DOI:
    10.1182/blood-2022-165458
  • 发表时间:
    2022-11-15
  • 期刊:
  • 影响因子:
    23.100
  • 作者:
    Joseph Rimando;Leslie Cope;Karen McKinnon;Benjamin G. Vincent;Sergio Rutella;Joshua F. Zeidner;Jonathan S. Serody;Ivana Gojo;Leo Luznik
  • 通讯作者:
    Leo Luznik
Clinical Activity of Anti-PD-1 Therapy Following CD30 CAR-T Cell Therapy in Relapsed Hodgkin Lymphoma
  • DOI:
    10.1182/blood-2022-156660
  • 发表时间:
    2022-11-15
  • 期刊:
  • 影响因子:
  • 作者:
    Timothy J. Voorhees;Anne W. Beaven;Christopher Dittus;George E Hucks;J. Kaitlin Morrison;Catherine Joyce Arago Cheng;Tammy Cavallo;Steven I. Park;Gianpietro Dotti;Jonathan S. Serody;Barbara Savoldo;Natalie S. Grover
  • 通讯作者:
    Natalie S. Grover
Alternative tumour-specific antigens
肿瘤特异性替代抗原
  • DOI:
    10.1038/s41568-019-0162-4
  • 发表时间:
    2019-07-05
  • 期刊:
  • 影响因子:
    66.800
  • 作者:
    Christof C. Smith;Sara R. Selitsky;Shengjie Chai;Paul M. Armistead;Benjamin G. Vincent;Jonathan S. Serody
  • 通讯作者:
    Jonathan S. Serody
<em>Characterization of a Cyclic Dinucleotide Metabolic Switch to Fuel Antitumor Immunity</em>
  • DOI:
    10.1182/blood-2022-169006
  • 发表时间:
    2022-11-15
  • 期刊:
  • 影响因子:
  • 作者:
    Jeremy A. Meier;Katie E. Hurst;David L. Corcoran;Jessica E. Thaxton;Jonathan S. Serody
  • 通讯作者:
    Jonathan S. Serody

Jonathan S. Serody的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Jonathan S. Serody', 18)}}的其他基金

SToP Cancer SPORE: Career Enhancement Program
STOP Cancer SPORE:职业提升计划
  • 批准号:
    10334089
  • 财政年份:
    2022
  • 资助金额:
    $ 16.51万
  • 项目类别:
SToP Cancer SPORE: Career Enhancement Program
STOP Cancer SPORE:职业提升计划
  • 批准号:
    10705618
  • 财政年份:
    2022
  • 资助金额:
    $ 16.51万
  • 项目类别:
Enhancing Innate Immune Reconstitution Post Allogeneic HSCT.
增强同种异体 HSCT 后的先天免疫重建。
  • 批准号:
    10297917
  • 财政年份:
    2021
  • 资助金额:
    $ 16.51万
  • 项目类别:
Enhancing Innate Immune Reconstitution Post Allogeneic HSCT.
增强同种异体 HSCT 后的先天免疫重建。
  • 批准号:
    10653130
  • 财政年份:
    2021
  • 资助金额:
    $ 16.51万
  • 项目类别:
Enhancing Innate Immune Reconstitution Post Allogeneic HSCT.
增强同种异体 HSCT 后的先天免疫重建。
  • 批准号:
    10470834
  • 财政年份:
    2021
  • 资助金额:
    $ 16.51万
  • 项目类别:
Mechanistic Evaluations of ILC2 Cells for the Treatment/Prevention of GVHD
ILC2 细胞治疗/预防 GVHD 的机制评估
  • 批准号:
    9403099
  • 财政年份:
    2017
  • 资助金额:
    $ 16.51万
  • 项目类别:
Mechanistic Evaluations of ILC2 Cells for the Treatment/Prevention of GVHD
ILC2 细胞治疗/预防 GVHD 的机制评估
  • 批准号:
    9918441
  • 财政年份:
    2017
  • 资助金额:
    $ 16.51万
  • 项目类别:
Mechanistic Evaluations of ILC2 Cells for the Treatment/Prevention of GVHD
ILC2 细胞治疗/预防 GVHD 的机制评估
  • 批准号:
    9528655
  • 财政年份:
    2017
  • 资助金额:
    $ 16.51万
  • 项目类别:
Th1/Th17 Macrophage Interactions in Cutaneous GVHD
皮肤 GVHD 中 Th1/Th17 巨噬细胞的相互作用
  • 批准号:
    9024463
  • 财政年份:
    2012
  • 资助金额:
    $ 16.51万
  • 项目类别:
Th1/Th17 Macrophage Interactions in Cutaneous GVHD
皮肤 GVHD 中 Th1/Th17 巨噬细胞的相互作用
  • 批准号:
    8626365
  • 财政年份:
    2012
  • 资助金额:
    $ 16.51万
  • 项目类别:

相似海外基金

Proton radiation therapy combined with immunotherapy for enhancing antitumor immune responses in pancreatic cancer murine models.
质子放射治疗与免疫治疗相结合,增强胰腺癌小鼠模型的抗肿瘤免疫反应。
  • 批准号:
    24K10423
  • 财政年份:
    2024
  • 资助金额:
    $ 16.51万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Development of a novel cancer immunotherapy model targeting human macrophages
开发针对人类巨噬细胞的新型癌症免疫治疗模型
  • 批准号:
    24K18516
  • 财政年份:
    2024
  • 资助金额:
    $ 16.51万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Development of a comprehensive microbial immunotherapy platform with immuno-transcriptomic monitoring for treatment of bladder cancer (DOCMI-BC)
开发用于治疗膀胱癌的具有免疫转录组监测的综合微生物免疫治疗平台(DOCMI-BC)
  • 批准号:
    10087336
  • 财政年份:
    2024
  • 资助金额:
    $ 16.51万
  • 项目类别:
    Collaborative R&D
In vivo function-persistent polymersome nanoreactor with tumor-specific activation and safe clearance/metabolism for synergistic oxidation-chemo-immunotherapy
具有肿瘤特异性激活和安全清除/代谢作用的体内功能持久聚合物纳米反应器,用于协同氧化-化学-免疫治疗
  • 批准号:
    24K21109
  • 财政年份:
    2024
  • 资助金额:
    $ 16.51万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Indication selection, patient stratification, and IND preparation for STX-002: the first-in-class LRG1 inhibitor for treatment of chronic kidney disease and immunotherapy-resistant tumours.
STX-002的适应症选择、患者分层和IND准备:用于治疗慢性肾病和免疫治疗耐药肿瘤的一流LRG1抑制剂。
  • 批准号:
    10092585
  • 财政年份:
    2024
  • 资助金额:
    $ 16.51万
  • 项目类别:
    Collaborative R&D
Anti-Complement Immunotherapy for Pancreatic Cancer
胰腺癌的抗补体免疫治疗
  • 批准号:
    10751872
  • 财政年份:
    2024
  • 资助金额:
    $ 16.51万
  • 项目类别:
Spatial-BrTME: Multicellular spatial dynamics of immunotherapy response in breast cancer
Spatial-BrTME:乳腺癌免疫治疗反应的多细胞空间动力学
  • 批准号:
    EP/Y014995/1
  • 财政年份:
    2024
  • 资助金额:
    $ 16.51万
  • 项目类别:
    Research Grant
Develop the novel targets and immunotherapy-combination agents through targeting nuclear transport receptor
以核转运受体为靶点开发新靶点和免疫治疗联合药物
  • 批准号:
    24K13116
  • 财政年份:
    2024
  • 资助金额:
    $ 16.51万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Innovative Lymphatic Immunotherapy for Metastatic Lymph Nodes
转移性淋巴结的创新淋巴免疫疗法
  • 批准号:
    23H00543
  • 财政年份:
    2023
  • 资助金额:
    $ 16.51万
  • 项目类别:
    Grant-in-Aid for Scientific Research (A)
Metachronous synergistic effects of preoperative viral therapy and postoperative adjuvant immunotherapy via long-term antitumor immunity
术前病毒治疗和术后辅助免疫治疗通过长期抗肿瘤免疫产生异时协同效应
  • 批准号:
    23K08213
  • 财政年份:
    2023
  • 资助金额:
    $ 16.51万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了